IL2 and neuroblastoma: The use of anti-GD2 mAbs, although largely beneficial for neuroblastoma patients with the use of anti-GD2 mAb Dinutuximab/IL-2/GM-CSF therapy, shows toxic side-effects such as allodynia due to the expression of GD2 on peripheral nerves.